Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | OGG1 | O15527 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 8/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1807646 | 0.92 | ALDH1A1 (0.64) | TDP1NOTUMALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1908607 | 0.89 | TP53 (0.70) | TP53ALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL15805636 | 0.83 | CA1 (0.52) | TDP1TP53ALDH1A1SMN1; SMN2OGG1 | |
| SCHEMBL9333835 | 0.82 | TDP1 (0.52) | TDP1TP53NOTUMALDH1A1SMN1; SMN2 | |
| SCHEMBL1021359 | 0.80 | NOTUM (0.64) | TP53NOTUMALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL29737158 | 0.80 | NOTUM (0.64) | TP53NOTUMALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL3183440 | 0.80 | KMT2A (0.44) | ALDH1A1KMT2ATSHR | |
| SCHEMBL1803594 | 0.80 | ALDH1A1 (0.67) | TP53NOTUMALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL12559522 | 0.78 | NOTUM (0.64) | TDP1TP53NOTUMALDH1A1LMNA | |
| SCHEMBL21678176 | 0.78 | NOTUM (0.64) | TDP1TP53NOTUMSMN1; SMN2OGG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | TDP1 4350/4885TP53 3890/4885NOTUM 76/4885 |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | TDP1 4350/4885TP53 3890/4885NOTUM 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.